2468-2942

Cancer Treatment and Research Communications

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 1239 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1239 DOIs
2

Attach ORCID iDs across 669 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact669 DOIs
3

Deposit reference lists for 25 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact25 DOIs

DOIs for this ISSN

Showing the top 5 of 1239 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Reco… (10.1016/j.ctarc.2020.100278)
Abstract ORCID
111.65 170
2 Tumor angiogenesis: Current challenges and therapeutic oppor… (10.1016/j.ctarc.2021.100422)
Abstract ORCID
110.07 158
3 Epithelial ovarian cancer: Review article (10.1016/j.ctarc.2022.100629)
Abstract ORCID
102.27 110
4 Biochemical predictors of response to immune checkpoint inhi… (10.1016/j.ctarc.2021.100328)
Abstract ORCID
95.15 79
5 Neoadjuvant therapy for cholangiocarcinoma: A comprehensive… (10.1016/j.ctarc.2021.100354)
Abstract ORCID
94.04 75
6 Role of immunotherapy in bladder cancer (10.1016/j.ctarc.2020.100296)
Abstract ORCID
92.56 70
7 First-line Chemotherapy in Advanced Biliary Tract Cancer Ten… (10.1016/j.ctarc.2021.100335)
Abstract ORCID
92.25 69
8 Appetite problem in cancer patients: Pathophysiology, diagno… (10.1016/j.ctarc.2021.100336)
Abstract ORCID
89.97 62
9 Pemigatinib: Hot topics behind the first approval of a targe… (10.1016/j.ctarc.2021.100337)
Abstract ORCID
89.62 61
10 Tumor-derived exosomal circFARSA mediates M2 macrophage pola… (10.1016/j.ctarc.2021.100412)
Abstract ORCID
88.17 57
11 Ins and outs of cadmium-induced carcinogenesis: Mechanism an… (10.1016/j.ctarc.2021.100372)
Abstract ORCID
86.21 52
12 Evaluation of cytotoxic activity of docetaxel loaded gold na… (10.1016/j.ctarc.2019.100157)
Abstract ORCID
83.60 46
13 KRAS mutation as a prognostic factor and predictive factor i… (10.1016/j.ctarc.2020.100200)
Abstract ORCID
82.66 44
14 The utility of serum tumor markers CEA and CA 15–3 for breas… (10.1016/j.ctarc.2021.100402)
Abstract ORCID
82.66 44
15 Syndecans in cancer: A review of function, expression, progn… (10.1016/j.ctarc.2021.100312)
Abstract ORCID
82.17 43
16 Uptake of a colorectal cancer screening blood test is higher… (10.1016/j.ctarc.2016.12.004)
Abstract ORCID
80.10 39
17 The use of heparin and heparin-like molecules in cancer trea… (10.1016/j.ctarc.2020.100192)
Abstract ORCID
80.10 39
18 Establishing patient-tailored variability-based paradigms fo… (10.1016/j.ctarc.2020.100240)
Abstract ORCID
78.41 36
19 Evaluation of body Computed Tomography-determined sarcopenia… (10.1016/j.ctarc.2019.100154)
Abstract ORCID
77.82 35
20 Utilization of systemic therapy for treatment of advanced ur… (10.1016/j.ctarc.2021.100325)
Abstract ORCID
77.82 35
21 Breast cancer risk prediction in African women using Random… (10.1016/j.ctarc.2021.100396)
Abstract ORCID
76.57 33
22 Immunotherapy in head and neck squamous cell carcinoma: An u… (10.1016/j.ctarc.2022.100649)
Abstract ORCID
75.26 31
23 Cardiotoxicity in breast cancer treatment: Causes and mitiga… (10.1016/j.ctarc.2023.100760)
Abstract ORCID
75.26 31
24 Personalized medicine: An alternative for cancer treatment (10.1016/j.ctarc.2024.100860)
Abstract ORCID
75.26 31
25 0,1,2,3D nanostructures, types of bulk nanostructured materi… (10.1016/j.ctarc.2024.100834)
Abstract ORCID
74.57 30
26 Changes in body weight in patients with colorectal cancer tr… (10.1016/j.ctarc.2016.09.002)
Abstract ORCID
73.86 29
27 Relationship between anti-depressant use and lung cancer sur… (10.1016/j.ctarc.2017.01.001)
Abstract ORCID
73.86 29
28 IDH inhibitors in advanced cholangiocarcinoma: Another arrow… (10.1016/j.ctarc.2021.100356)
Abstract ORCID
73.86 29
29 Cancer patients and COVID-19: Mortality, serious complicatio… (10.1016/j.ctarc.2020.100285)
Abstract ORCID
73.12 28
30 The regulation of cyclin D promoters – review (10.1016/j.ctarc.2021.100338)
Abstract ORCID
73.12 28
31 Autophagy Modulation and Cancer Combination Therapy: A Smart… (10.1016/j.ctarc.2022.100512)
Abstract ORCID
73.12 28
32 Emerging theranostic gold nanostructures to combat cancer: N… (10.1016/j.ctarc.2020.100258)
Abstract ORCID
71.57 26
33 Circulating biomarkers for monitoring therapy response and d… (10.1016/j.ctarc.2021.100410)
Abstract ORCID
70.75 25
34 Efficacy of Bacillus clausii UBBC - 07 spores in the amelior… (10.1016/j.ctarc.2022.100523)
Abstract ORCID
70.75 25
35 Etoposide and topoisomerase II inhibition for aggressive pro… (10.1016/j.ctarc.2020.100221)
Abstract ORCID
69.90 24
36 Dietary acid load and lung cancer risk: A case-control study… (10.1016/j.ctarc.2021.100382)
Abstract ORCID
69.90 24
37 Granulocyte-colony stimulating factor-associated aortitis in… (10.1016/j.ctarc.2021.100454)
Abstract ORCID
69.90 24
38 The clinical behavior of different molecular subtypes of bre… (10.1016/j.ctarc.2021.100469)
Abstract ORCID
69.90 24
39 Lifetime physical inactivity is associated with lung cancer… (10.1016/j.ctarc.2018.01.001)
Abstract ORCID
69.01 23
40 A single institution study evaluating outcomes of PD-L1 high… (10.1016/j.ctarc.2021.100330)
Abstract ORCID
67.12 21
41 Immunotherapy in multiple myeloma (10.1016/j.ctarc.2021.100468)
Abstract ORCID
67.12 21
42 Pleiotropic effects of nutritional ketosis: Conceptual frame… (10.1016/j.ctarc.2017.06.001)
Abstract ORCID
66.11 20
43 Is human papillomavirus associated with breast cancer or pap… (10.1016/j.ctarc.2019.100122)
Abstract ORCID
66.11 20
44 Online information seeking behaviors of breast cancer patien… (10.1016/j.ctarc.2020.100176)
Abstract ORCID
66.11 20
45 Mitochondria-targeted magnolol inhibits OXPHOS, proliferatio… (10.1016/j.ctarc.2020.100210)
Abstract ORCID
66.11 20
46 Knowledge and practice regarding prostate cancer germline te… (10.1016/j.ctarc.2020.100212)
Abstract ORCID
66.11 20
47 Utilization of systemic treatment for metastatic bladder can… (10.1016/j.ctarc.2020.100266)
Abstract ORCID
66.11 20
48 Linking hsp90’s role as an evolutionary capacitator to the d… (10.1016/j.ctarc.2021.100400)
Abstract ORCID
66.11 20
49 Predictive factors associated with radiation dermatitis in b… (10.1016/j.ctarc.2021.100403)
Abstract ORCID
66.11 20
50 Real-world patterns of biomarker testing and targeted therap… (10.1016/j.ctarc.2022.100522)
Abstract ORCID
66.11 20